Researchers explore impact of hair products on breast cancer risk

NewsGuard 100/100 Score

Can use of hair products have an impact on breast cancer risk for women? That is a question explored by Rutgers University investigators – and colleagues from Roswell Park Cancer Institute, Massachusetts General Hospital and Moffitt Cancer Center. Lead author of the work Adana A.M. Llanos, PhD, MPH of Rutgers Cancer Institute of New Jersey and Rutgers School of Public Health along with author Elisa V. Bandera, MD, PhD of Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School and Rutgers School of Public Health share more about the work which examined use of hair dyes, hair relaxers and cholesterol-based hair products in African-American and Caucasian women. The work appears in the June 2017 online issue of Carcinogenesis (doi: https://doi.org/10.1093/carcin/bgx060).

Q: Why is this topic important to explore?

A: Evidence from previous studies, including some experimental studies on animal models and some epidemiologic studies, suggest that exposure to some compounds found in hair products may be a risk factor for developing cancer. But studies that have been done in limited populations have focused mostly on hair dyes, and have yielded mixed findings.

Q: How was this study structured?

A: A total of 4,285 African American and Caucasian women with breast cancer cases and controls (women without breast cancer) who were aged 20 to 75, recruited from New York City and ten New Jersey counties through 2014 and were participants in the Women's Circle of Health Study were analyzed. The New Jersey State Cancer Registry was involved in identification of breast cancer cases in New Jersey. We collected socio-demographics and established probable breast cancer risk factors, including: family and personal health history, prenatal exposures, reproductive history and hormone use, and lifestyle exposures (e.g., hair product use, tobacco smoke exposure, alcohol consumption, physical activity, vitamin use) from all participants. We also collected breast tumor characteristics from all breast cancer patients in the study. We were particularly interested in participants' use of hair dyes, chemical relaxers/straighteners and deep conditioning creams containing cholesterol or placenta and how using these hair products may relate to their breast cancer risk.

Q: What did you learn?

A: We found that use of dark shade hair dyes (dark brown or black) was associated with a 51 percent increased overall risk of developing breast cancer among African American and Caucasian women, and a 72 percent increased risk of estrogen receptor positive breast cancer among African Americans. We also found that use of chemical relaxers or straighteners was associated with a 74 percent increased risk among Caucasians, with some differences in breast cancer risk observed by estrogen receptor status.

Q: What is the implication of these findings?

A: These novel findings provide support of a relationship between the use of some hair products and breast cancer risk. Our findings highlight the need for further examinations of the link between the use of hair products as important exposures that may contribute to the development of breast cancer, as well as ways to reduce the associated risks.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First FDA-approved cellular therapy for metastatic melanoma available in South Florida